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MULTIPARAMETRIC 3 TESLA MAGNETIC RESONANCE IMAGING 
AS A CLINICAL TOOL TO CHARACTERIZE PROSTATE CANCER 
MATTHEW CHRISTOPHER DUNN 
ABSTRACT 
 Scientists have come a long way in understanding prostate cancer as a 
disease and how its progression affects the men who develop it.  Prostate 
adenocarcinoma may be present without causing clinical symptoms.  Prostate 
cancer may metastasize, which increases the likelihood of fatality.  The cause of 
the disease is still not completely clear, but genetics, race, tissue damage, 
history of previous infections, diet, and environmental influences appear to play a 
role in its development.  Magnetic resonance imaging (MRI) has become an 
excellent clinical tool to characterize prostate cancer without the use of ionizing 
radiation or surgery.  It is concluded that MRI is the optimal imaging modality to 
achieve detection, characterization, and staging of intracapsular and 
extracapsular prostate disease.  The advances in MRI technology, particularly 3 
Tesla, allows for reduced surgical intervention thus improving quality of life for 
patients with the disease. 
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INTRODUCTION 
 
 Prostate anatomy and the pelvic environment facilitate the development of 
multiple diseases.  Carcinoma of the prostate is common in men in the 
developed world, with racial differences putting some populations at greater risk.  
Since the 1980s, the digital age has increased knowledge of the prostate 
environment.  MRI of the prostate has slowly gained popularity, until now, where 
the modality has surpassed the other modalities in the clinical setting.  This paper 
will paint illustrate the current environment of clinical prostate magnetic 
resonance imaging that is not just medical, but political, social, and economical. 
The Prostate 
The pelvic region of the human body is full of vital organs for the species 
to survive.  The organs in this region are involved in reproduction, nutrient 
retention, blood supply to lower extremities, and excretion.  One of these organs 
is only to be found in male pelvis, the prostate.  The prostate is a part of the male 
reproductive system as an unpaired accessory structure.  The prostate gland is 
located at the proximal end of the urethra after it has left the urinary bladder and 
anterior to the rectum.   
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Figure 1: Prostate and the Male Pelvis 
 
left = coronal view; right = sagittal view 
This artistic depiction of the organ allows for understanding of how clinicians 
think of the gland as an avenue for disease. These drawings provide information 
to assist in the diagnosis, staging, and treatment of possible disease (Coakley 
and Hedvig, 2000). 
 
The size of this organ varies over the age of a man and grows in volume 
over time.  Prostate tissue consists of about thirty to fifty compound 
tubuloalveolar glands (epithelial elements), surrounded by and wrapped in a very 
thick layer of smooth muscle fibers (stromal elements).  The gland primarily 
consists of cells that function to produce exocrine or endocrine secretions. Basal 
epithelial cells of the prostate tend to be the biggest source for the initiation of 
carcinoma of the prostate (PCa) tumors.  Continuation or maintenance of the 
tumor is by luminal like epithelial cells (Stoyanova et al, 2013).  The glands within 
the prostate serve an important function in the male reproductive system.  They 
each produce an acidic solution that, when needed, is added to the semen flow 
during ejaculation.  In fact, the liquid contributes between twenty and thirty 
percent of the total exiting semen volume.  The secretions are passed through 
the prostatic urethra, where movement occurs due to the contractions of the 
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muscular prostate wall (Martini and Nath, 2010; McPhee and Hammer, 2010; 
Drake et al, 2010). 
It is important to understand conventional medicine’s partitioning of the 
prostate into three zones, consisting of the peripheral zone (PZ), central zone 
(CZ), and transition zone (TZ) of the gland.  The PZ is the outer region of the 
prostate, and is well known to be very sensitive to androgen levels.  The zone is 
consistently has higher incidence of PCa than the other regions of the gland.  
Androgens are hormones that affect or stimulate the maintaining or developing of 
male attributes by coming together with androgen receptors (ARs).  This 
contributes to PCa, which is substantiated by evidence that PCa is inhibited or 
does not develop when males undergo an orchiectomy or if they are castrated 
prior to puberty (Kumar et al, 2007).  The CZ is the inner region of the prostate 
gland, which tends to be very sensitive to estrogen and have higher incidence of 
benign prostatic hyperplasia (BPH) relative to other regions of the gland.  The TZ 
of the prostate gland is the area in direct proximity to the urethra (McPhee and 
Hammer, 2010).  This zone contains ducts and stromal tissue that helps 
transport prostatic fluid.  The TZ came about due to comprehension of BPH and 
was a term developed by John E. McNeal in 1978 (Selman, 2011). 
Cancer and the Prostate 
Diseases of the prostate are complex and require understanding the 
environment where the prostate tissue exists in order to have a complete 
comprehension of origination.  The prostate gland has two major ducts that 
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converge inside the organ to focus the outward flow of the fluids through one 
duct to exit through the penis.  In addition, the prostate gland sometimes has 
added pressure from the bladder and the rectum, which are adjacent to the 
prostate, as they perform their bodily functions.  This puts the prostate at risk 
from irritation internally and externally, and subsequently inflammation as a 
response to injury.  Bacteria is another avenue for disease in the gland by 
traveling up or down the ducts into the prostate, for example chlamydia.  Another 
intensely studied epidemiological aspect of disease in the organ is genetics, both 
inherited deoxyribonucleic acid (DNA) mutations and related DNA mutations.  
Genetic abnormalities can cause the various cell types in the prostate to replicate 
uncontrollably.   
Diseases that are common to the prostate include various types of 
prostatitis, benign prostatic hyperplasia (BPH) and carcinoma.  Prostatitis is 
swelling and inflammation of the prostate gland.  The swelling or inflammation is 
a response to injury and sometimes occurs in conjunction with infections that can 
be a result of bacterial presence.  This type of disease in the gland is 
characterized by several factors, which include but are not limited to: neutrophilic 
inflammatory infiltrate, stromal edema, glandular injury, lymphoid infiltrate, 
fibroblastic proliferation, foamy histiocytes, eosinophils, bacterial presence, 
microabscess formation, and leukocytic infiltration.  On a larger scale, prostatitis 
can cause clinical symptoms, such as fever, pelvic pain, lower back pain, 
urination frequency changes, and even dysuria (Kumar et al, 2007).  Onset of 
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prostatitis can also be caused by procedures on the prostate, such as biopsies, 
where the injury to the gland elicits a response of inflammation and swelling.   
Another common disease is hyperplasia of the prostate gland, which is 
known as nodular hyperplasia of the prostate or benign prostatic hyperplasia 
(BPH), glandular hyperplasia, or stromal hyperplasia.  Hyperplasia describes an 
increase in the number of cells in tissue and organs as a response to pathologic 
or physiologic alterations to the normal state.  This disease is readily identifiable 
by utilizing the medical imaging modality, magnetic resonance imaging (MRI).  
Hyperplasia is found to be most prevalent in the transitional and central zones of 
the gland.  Histologically, BPH is characterized by stromal and epithelial cells that 
have proliferated in the gland resulting in the enlargement of the gland and 
leading to possible obstruction of urinary flow.  Other important morphology is 
that the disease forms nodules that are either solid or have cystic spaces (Kumar 
et al, 2007).   
Unfortunately, BPH is not completely understood, but most theories point 
to the impact of hormonal influence.  Research has shown androgens as the 
focus, citing that men with nodular hyperplasia have drastically increased 
stimulation of dihydrotestosterone, 3-alpha-androstandediol, and 5-alpha-
reductase.  Treatments have involved using inhibitors to prevent hormones from 
connecting with their receptors, such as the 5-alpha-reductase inhibitor.  Males 
do not develop this condition when the testicles are removed prior to entering 
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puberty.  This is informative because it verifies that hormones are involved, but it 
also suggests age as a factor (Kumar et al, 2007). 
The most common cancer of the prostate is carcinoma of the prostate.  
Prostate cancers are mostly represented as prostate adenocarcinomas (about 
95%), and about 5% of the carcinomas are squamous cell carcinoma, signet-ring 
carcinoma, transitional carcinoma, neuroendocrine carcinoma or sarcoma 
(Alivatos and Pavlos, 2014).  Similar to BPH, this disease does not develop in 
males that have had their testicles removed (known as orchiectomy) prior to the 
initiation of puberty (Kumar et al, 2007).  This links hormonal stimulation to the 
disease progression, more specifically androgens.  Research has shown that 
there may be genetic and environmental links.  The cancer develops primarily in 
the PZ of the prostate, but may develop in the CZ or TZ, especially in advanced 
stages of the disease (Kumar et al, 2007; McPhee and Hammer, 2010).  The PZ 
tumors are palpable by digital rectal exam (DRE) because they tend to be hard 
nodules that are irregular in shape.   
Early on, the disease tends to be of an ill-defined mass or masses, with 
margins that are difficult to differentiate.  The carcinoma starts in the prostate 
gland, after which it spreads to the seminal vesicles (SV) and pelvic lymph nodes 
(PLNs).  This is frequently followed by metastatic tumors in the urinary bladder 
wall and local pelvic bone structures.  Clinically these are rare manifestations in 
the early stages of the disease.  The disease tends to be discovered after a 
series of tests, such as the DRE, and the blood lab test measuring prostate 
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specific antigen (PSA).  The disease can have high rates of entering remission, if 
the disease is caught early on, meaning prior to escaping the capsule of the 
prostate gland.  The disease is generally characterized by a combination of test 
results that include the PSA blood test, biopsy, and imaging of the gland and 
surrounding tissues and structures.  These tests provide information to guide 
clinicians in grading the tumor burden of the individual. 
Socioeconomics 
Carcinoma of the prostate is a social and an economic disease.  This type 
of cancer appears primarily in developed countries of world.  Not only that, but 
the most developed countries, such as the United States of America (USA) and 
countries in Europe, are where essentially the majority of the incidence are 
located on a yearly basis.  The USA has the highest incidence of prostate 
carcinoma with hundreds of thousands of new prostate adenocarcinoma 
incidents each year and rising.  This trend is substantiated in the literature.  In 
1999 there were 167,439 new cases of prostate adenocarcinoma (U.S. Cancer 
Statistics Working Group, 2013), and 189,000 new cases of prostate cancer and 
30,200 prostate cancer related deaths in 2002 (National Cancer Institute, 2012).  
These rates rose to 192,280 new cases and 27,360 deaths related to prostate 
cancer in the USA in 2009 (American Cancer Society, 2009).  Recently in 2013, 
the number of new cases reached 238,590 with 29,720 deaths related to the 
disease (Crawford et al, 2014). 
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Table 1: Center of Disease Control’s US Cancer Statistics 1999 and 2010 for 
Prostate Cancer 
 1999 2010  
Race Incidence Mortality Incidence Mortality 
White 152.4 23.1 130.1 19.1 
Black 148 31.2 146.7 24.1 
Asian/Pacific Islander 52.5 5.5 48.5 5.1 
American Indian/Alaska Native 38.2 4.5 37 5.4 
Hispanic 54.6 6 49.6 6 
Rates written as per 100,000 people compares incidences and mortality rates of 
prostate cancer by race in the United States of America (U.S. Cancer Statistics 
Working Group, 2013). 
 
Looking at the statistics of a country’s trends and raw numbers, such as 
the USA, is a difficult task because of all the variations in data collection 
processes.  The connection is possible when examining a particular state or city, 
for example Massachusetts and Boston.  Boston serves as a model microcosm 
for the disease in the USA when looking at prostate cancer data.  This is verified 
by the incidence rate of prostate cancer which closely matches the national 
incidence of recent prostate cancer trends (Boston Public Health Commission, 
2011; American Cancer Society, 2014).   
 
Figure 2: Prostate Cancer Incidence 
 
Prostate Cancer Incidence for male residence of Boston, Ma from 1998 through 
2007 by race (Boston Public Health Commission, 2011). 
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The trends in the incidence rates when comparing races, are similar in 
that Black males tended to have the highest incidence of prostate 
adenocarcinoma, followed by Caucasian males, while Asian men tended to have 
the lowest incidence (Massachusetts Department of Public Health, 2012; Boston 
Public Health Commission, 2010; American Cancer Society, 2014; Siegel et al, 
2014).  Black residents of Boston have reported socioeconomic challenges that 
are shown to be disproportionately higher when compared to other Caucasian 
residents.  They have significantly higher infant mortality rates, exposure to 
violence, higher rates of diabetes and higher hospitalization for heart disease 
(Boston Public Health Commission, 2010).  Black men are disproportionately at a 
disadvantage in Boston, historically, from a social and economic perspective.  
This group of the population in Boston has high rates of poverty, 
underemployment, incarceration, lower amount of educational achievement, and 
higher rates of prostate cancer compared to other racial groups in Boston 
(Boston Public Health Commission, 2011; Boston Public Health Commission, 
2013). 
Molecules, Genetics, Race 
Genetic testing at a genome wide level in each individual is providing a 
huge increase in understanding PCa and how it develops.  Research has been 
focused on genetic susceptibility to PCa comparing various ethnicities, 
particularly men of European descent compared to men of African descent.  The 
focus has been on androgen receptor activity, genes related to prostate cancer, 
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and methylation, which have been related to race, diet, age, and the environment 
(Farrell et al, 2013).  Research has shown, based on primary tumor analysis, 
which metastatic promoting genes are found to be more highly expressed in 
African American samples compared to European American samples when using 
microarray technology (Powell et al, 2013). 
The androgen receptor gene (AR gene) located on chromosome Xq11-12 
is of particular interest as its first exon code has shown to be significantly 
different between African-Americans and Caucasian-Americans.  This relates to 
the number of CAG repeats.  The risk of developing and degree of 
aggressiveness of the prostate cancer is increased in populations with fewer 
CAG repeats, which African-American males tend to have significantly fewer of 
them compared to their Caucasian-American counterparts.  This is supported by 
evidence demonstrating reduced CAG repeats allows for the increased likelihood 
of androgen-driven prostate adenocarcinoma.  The genetic structure of the 
androgen receptor is of importance, but the overall genomic function of the 
androgen receptor is just as essential.  Research has found that this particular 
genetic structure is significantly higher in African-Americans compared to other 
populations (Farrell et al, 2013). 
Studies have reviewed inheritance and risk of PCa, especially since there 
appear to be racial differences in incidence.  Epidemiology studies have found 
that a man’s risk of developing prostate cancer is 2.5 times as likely if they have 
a first-degree family member that has it, 3.37 times as likely if they have a 
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brother with it, 2.17 times as likely if they have an affected father, and 5 times as 
likely if they have two or more first-degree relatives with PCa.  Over thirty-five 
alleles have been identified as inherited and associated with prostate cancer, and 
there are differences between African-Americans and Caucasian-Americans 
(Farrell et al, 2013). 
Heritance and AR understanding in relation to prostate cancer allows for 
comprehending part of the puzzle that genetics of prostate cancer involves.  The 
next piece of the puzzle is epigenetics, more specifically, methylation.  Research 
compared prostate cancer tissue in African-Americans versus Caucasian-
Americans in the amount of methylation of known genes.  It was found that 
regulatory gene of prostate disease, including SPARC, TIMP3, AR, and NKX2-5 
had greater levels of methylation in African American prostate cancer tissue 
compared to their Caucasian American counterparts (Farrell et al, 2013).  
Another study found in addition to AR, SPARC, and TIMP3 that RARbeta2 and 
GSTP1 have higher methylation prevalence in African Americans compared to 
Caucasian American males when analysis was done on normal prostate and 
PCa tissues samples.  While methylation increases with age, the significance in 
the above findings is that it is above and beyond what is considered normal 
(Kwabi-Addo et al, 2010). 
Categorizing the Malignancy 
The carcinoma of the prostate is typically a slow growing disease for most 
in whom the disease develops.  The first step is determine who has the disease 
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through screening using the prostate specific antigen (PSA) test and digital rectal 
exam (DRE).  It is important to determine what type of prostate cancer that 
patient has, level of progression and degree of aggressiveness.  Prostate cancer 
is characterized by multiple tests and/or grading systems in what is called 
“staging”.  These include Gleason scores based on biopsies and prostatectomy, 
TNM staging documentation and imaging results.  Staging is defined as the 
“extent or severity of a person’s cancer” (National Cancer Institute, 2013).  The 
previous mentioned are usually done in some combination to provide a multiple 
approach point of view to inform clinicians of the presenting patient’s prostate 
health or disease.  The utilization of diagnostic tests prevents the need for 
exploratory surgery and improves standard of care for the patients involved. 
The DRE is generally the first test men experience in regards to prostate 
health, which is the initial screening step.  This exam has been important to 
finding the disease in men and considered part of primary care physicians’ 
annual physical exam for adult males by the age of 40 years old, but could be 
done earlier for men with relative(s) that have a history of prostate cancer.  
However, the doctors that use this technique are not guaranteed to find 
malignancies.  The obstacles that are faced are the limited capability of the 
technique, finger sensitivity of the doctor performing the exam, doctors’ expertise 
with technique, and interobserver variability.  New doctors are relying less and 
less on the DRE and focusing their base of information on imaging and other 
forms of technology. 
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The other test that may be performed separately or in conjunction with the 
DRE is a blood based laboratory test.  The test is known as the prostate specific 
antigen (PSA) test, which is part of the screening process for prostate cancer.  
The blood test measures the antigen levels of PSA at nanogram per milliliter 
levels.  The value is based on the premise that prostates produce prostate 
specific antigens.  The levels vary dependent on the individual and age with 
respect to glandular health, but there are general guidelines what is considered 
healthy, abnormal or biochemical failure.  The understanding is that a man’s PSA 
level will rise with age, but a certain increase from two consecutive blood tests or 
more would indicate various changes in health. 
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Figure 3: Prostate Specific Antigen Testing Rates 
 
Male residents of Boston’s prostate specific antigen testing rates for 2008 by 
various demographics.  The asterisks are for demographics with insufficient data 
(Boston Public Health Commission, 2010). 
 
Doctors consider a serum PSA value of 4.0 ng/mL or lower as in the normal 
range, but with a value that is above that range, doctors tend to recommend a 
biopsy to localize possible disease and extent of disease (National Cancer 
Institute, 2012; Barentsz et al, 2012). 
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Figure 4: Gleason Score Morphology of the Prostate 
               
Depiction of the tissue structure or morphology that was considered visible in 
biopsy for each of the grades (Delahunt et al, 2012). 
 
A patient that has a positive DRE and an elevated PSA serum value will 
proceed to have a prostate biopsy.  The histology of the prostate biopsy is 
evaluated using the Gleason grading system to assess prostate tissue pathology.  
The Gleason grading concept is based on the premise that it should be graded 
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on the basis of just the architectural pattern of the tumor.  The grading is given 
based on pattern categories of one (lowest grade) to five (highest grade).  The 
score a patient receives is based on clinicians adding up the primary and 
secondary pattern category grades, which can be the same.  The range of the 
scoring is two to ten, where two is the lowest score and may indicate that the 
sample is not cancer, while a ten is considered the most advanced stage of 
cancer.  This scoring system is usually used in conjunction with other testing 
methods to discern health of the prostate tissues (Epstein et al, 2005).   
The classification systems used in staging of carcinoma of the prostate 
are TNM and D’Amico.  The TNM Classification of Malignant Tumours 7th edition 
went into effect in 2010 and has been the standard for staging PCa in patients.  
The system relies on physical exam, imaging, laboratory tests, pathology reports, 
and surgical reporting results.  The analysis of data informs clinicians about the 
primary tumor in size and extent; nodular disease in the amount of spread to 
local lymph nodes; and metastatic disease spread to other body parts and 
possible secondary tumors.  This system is used on an international scale and 
recently there has been a push for improved standardized grading to limit 
interobserver variability and incorrect grading (Alivatos and Pavlos, 2014; 
National Cancer Institute, 2013).  The D’Amico Risk Classification is a method of 
arranging patients with prostate cancer that have had surgery into low, 
intermediate, and high risk groups for biochemical failure suggesting recurrence 
according to TNM staging at the clinical level, Gleason score from biopsy, and 
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pre-surgical PSA serum level.  This model is used generally in conjunction with 
other tests.  There is evidence that the relevance of this method may be 
becoming irrelevant based on shifting patient population (Hernandez et al, 2007). 
Imaging is what holds the key in today’s world of clinical medicine to 
characterize prostate cancer in a more complete manner without necessarily 
needing surgery or biopsy.  The modalities and their abilities have been tested 
with prostate cancer, some since before 1985.  Clinical imaging of the prostate is 
constantly evolving over time as doctors learn new techniques and realize limits 
of other imaging modalities. 
Imaging Techniques 
Imaging has been at the center of the evolution in understanding of PCa.  
Imaging has come a long way from histology imaging to digital modalities, such 
as positron emission tomography (PET), single-photon emission computed 
tomography (SPECT), computed tomography (CT), ultrasound (US), bone 
scintigraphy (BS), and magnetic resonance imaging (MRI).  These imaging 
modalities each have made contributions individually, in various combinations.  
Imaging has become standard to the clinical practice of diagnosing and staging 
of the disease.  Imaging is complicated by trade-offs because some modalities 
provide fast imaging with poor resolution, while others take more time with better 
resolution.  Some of the modalities emit ionizing radiation to patients, which adds 
to the risk a patient gains in order to be diagnosed, to localize treatment or to 
stage the disease. 
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Figure 5: Microbubble Contrast Enhanced Ultrasound 
 
Microbubble contrast enhanced ultrasound through mid-gland with arrow pointing 
to vascular bunch suggesting tumor (Trabulsi et al, 2010). 
 
The imaging modality that developed as a novelty to be the most preferred 
imaging technique by doctors the world is transrectal ultrasound (TRUS) 
technique.  The typical image for the 2D gray scale TRUS is one that has the 
prostate in the field of view and a lesion that is hypoechoic.  This image is in 
stark contrast to the sonograph of the normal prostate, which is one that has an 
echo pattern that is uniform.  The 3D gray scale TRUS technique is one that is 
helpful for localizing extracapsular disease, but has similar sensitivity and 
specificity compared to the 2D gray scale TRUS.  The Doppler US technique 
relies on blood flow rates in the case of imaging of the prostate and the possible 
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tumor will have different glow then the normal tissues it is surrounded by.  
Doppler is more time consuming and carries higher costs when compared to 2D 
or 3D gray scale TRUS options.  Ultimately, this form of US is not suggested for 
prostate cancer as it has yet to be proven as a better option than the 2D TRUS.   
Compression elastography, otherwise known as strain elastography, looks 
at the differentiation of tissue stiffness as it reacts to an applied force from US.  
This technique provides the 3D volume rendering with more details that help 
doctors understand the lesion(s) better, especially those located in the peripheral 
zone.  These more detailed results allow for better staging and treatment 
planning.  The other clinical elastographic technique is known as shear wave 
elastography.  Shear wave is where a color coded image is superimposed on a 
B-mode image, and in the prostate that means the region(s) that are dark blue 
are possible lesion(s).  When deciding which of the elastographic techniques to 
use, the shear wave method takes less time, but requires the tradeoff of needing 
more training to operate correctly.   
The last US technique to be discussed is contrast enhanced ultrasound 
(CE-US).  The CE-US technique utilizes highly echogenic microbubble contrast 
agents, where injectable gas is contained within a supporting shell.  This allows 
for increased visibility of density vascular regions of the prostate, which is 
correlated with prostate adenocarcinoma lesions.  If and when patients need a 
biopsy, it has become rather standard to use US to guide how and where the 
need to collect the biopsy is placed.  US allows for more effective planning in 
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biopsy locations, which gives clinicians a higher rate of retrieving a sample of the 
tissue in question and not missing the tissue.  This modality has seen many 
advances in machine finesse, pulse decisions, and refining of known methods, all 
while the digital world has evolved as well.  US has been utilized most effectively 
in helping define possible malignancies in the prostate, where tissues are in 
contrast to one another.  The following modalities will illustrate methods that help 
inform doctors of possible metastasis in the patients (Uchida et al, 2009; Seitz et 
al, 2011; Alivatos and Pavlos, 2014). 
Nuclear medicine has developed several techniques, one is bone 
scintigraphy (BS).  BS is sensitive to detecting bone and joint disease.  The 
diseases it tends to illuminate are bone metastatic tumors, benign bone disease, 
and a whole list of degenerative joint disease.  BS has become highly important 
in efficiently providing disease localization within a patient in one scan.  There 
are a few issues that make this a less than absolute decision to use this modality.  
One is that ionizing radiation is administered, by way of tracers such as 
methylene diphosphonate (MDP) labeled with Technetium 99m (Tc-99m).  This is 
a rather controversial issue, but usually when it comes to this modality it is a 
complete necessity.  Another reason is that while BS is effective at localizing 
disease in the bone and joints, it is not specific.  What appears suspicious on the 
images could be bone metastatic tumor(s) from prostate cancer, but it could be 
Paget’s disease among many possibilities (Alivatos and Pavlos, 2014).  
Suspicious uptake regions could be something else besides disease; it could be 
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bone scan “flare”.  Correctly reading these exams is a difficult task for complex 
patient cases leading to interobserver variability.  This can be limited by the use 
of manual or automated (use of computer-assisted diagnosis (CAD) software) 
(Tait et al, 2014).  A weakness that is known, but not always thought of when 
analyzing BS is the images are of the secondary effects the tumor has on the 
skeleton, known as osteoblastic reaction, and not the tumor proliferation.  This 
knowledge helps us make sense of the finding that micro-infiltrations by tumor 
lesions are not detectable (Crawford et al, 2014). 
Bone scintigraphy lacks in providing planar diagnostic accuracy; the other 
modalities of nuclear medicine, which have the ability to be combined with x-ray 
technology have helped refine and improve scintigraphy.  The options that are 
currently in use are single-photon emission computed tomography (SPECT) and 
positron emission tomography (PET) for prostate cancer.  SPECT and PET may 
be stand along modalities, but can be combined with computed tomography 
(CT).  From the point of view of radiotherapy, PET is part of a type of imaging 
coined as theragnostic imaging.  In theragnostic imaging, molecular imaging is 
introduced to allow clinicians to draw and selectively treat each of the voxels of 
tumor volume with dose painting based on the biological and functional 
characterization (De Bari et al, 2014).  PET and SPECT are valuable at providing 
3D views of the patients with the use of radioactive isotope tracers that the 
human body is able to absorb (uptake), and exit the body through excretions 
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after time passes.  Both use sugar to see how the possible tumor(s) or lesion(s) 
metabolize it, typically fluorodeoxyglucose (FDG) is preferred carrier of the label.   
If an institute has the ability to have a cyclotron on site, than the best 
tracer based on current publications is the carbon-11 (11 C) isotope because it 
has a blood clearance of five minutes and rapid uptake in prostatic tissue that is 
between three and five minutes.  The isotope requires this because there is a 20 
minute half-life.  Unfortunately, many institutions can-not afford financially or 
physically to have such a device, so the isotope is usually fluorine-18 (18F) or 
technetium-99 (99Tc) that is attached to something such as choline (Cho), 
sodium fluoride (NaF), MDP (phosphonate), or FDG (glucose analog).  These 
modalities struggle to provide high value information to clinicians as 
fluorodeoxyglucose (FDG) has a low uptake otherwise known as low avidity.  
Thus, these modalities combined with computed tomography provide accurate 
anatomical mapping.  This allows for the regionalization of possible lesion(s).   
The combined modalities allow for coregistration of imaging results.  The 
fused images make possible the identification of nuances that would have a 
chance of being missed.  The combination of the modalities does not change the 
fact that prostate cancer cells have low FDG uptake, which only further 
compounds the fact that doctors today are looking for small tumors.  Published 
research only further complicates any stance on the use of 18F-FDG as there are 
varied results for clinical trials (Alivatos and Pavlos, 2014; De Bari et al, 2014).  
The focus and strength of combining modalities is that it provides molecular or 
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metabolic information, and morphological or anatomical information.  This leads 
to sensitivity, specificity, and accuracy improvement. 
 
Figure 6: PET and CT Fusion 
 
Bone positron emission tomography imaging utilizing Flourine-18 sodium fluoride 
for patient with castrate resistant prostate cancer fused with computed 
tomography (Leung et al, 2014). 
 
A primary example of this is when PET and CT are combined, sensitivity 
and accuracy reaches a diagnostic level locating lymph node metastatic tumor 
lesions (Kitajima, 2014).  Choline PET/CT is considered by some as the optimal 
imaging modality for assessing the viable prostate cancer tumor lesion burden in 
the skeleton, but there is debate about its predictive value in early recurrence 
state.  The contention is due to no clear guideline agreement on the correct 
serum PSA value for patients to be at biochemical failure, to decide to use 
choline PET/CT.  Evidence is variable, with studies using different clinical and 
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pathological characteristics for their sample and different sample sizes.  The 
other fact is that choline PET/CT sensitivity changes in relation to initial tumor 
burden, previous biochemical failure, and the patient’s age.  There is some early 
evidence that choline PET/CT might appear to be acceptable in illuminating the 
local relapse of prostate cancer, if the patient has a serum PSA value great than 
1.4 ng/mL.   
When looking at lymph nodes, radiation oncologists struggle to determine 
treatments when they have elevated serum PSA value and there is choline PET 
uptake in some lymph nodes.  They are left to make difficult decisions to treat 
just the positive nodes or to include the area of the nodes because micro 
metastatic infiltration is undetectable (De Bari et al, 2014).  The other 
combination modality is SPECT/CT, which has improved lesion contrast and 
detection capability relative to bone scintigraphy (2014 & SMR & Ghosh). 
MRI of the Prostate 
Prostate cancer magnetic resonance imaging (PCa MRI) is and has been 
complex and multifaceted.  Since the early testing in mid to late 1980s, MRI has 
developed in the way it is used, understood, utilized, and implemented.  The 
imaging modality’s evolution has been one of science, financial gain, patient 
care, and politics.  Prostate cancer multiparametric MRI (PCa mpMRI) has 
started to reach the world stage.  Various organizations around the world are 
starting to form guidelines for scanning protocols, scanning equipment, among 
other aspects of prostate mpMRI. 
 25 
METHODS 
 
MRI Sequences 
Prostate MRI sequences are constantly evolving and new sequences are 
being tested as they come into development.  The first sequences utilized in the 
early days of prostate MRI, which would be early to late 1980s, were simple in 
sequence selection.  There were just the T1-weighted (T1-w) and T2-weighted 
(T2-w) sequences.  As time went on and innovations were made, other 
sequences came into the clinical setting.  These sequences included dynamic 
contrast enhanced (DCE), diffusion weighted imaging (DWI), and magnetic 
resonance spectroscopy (MRS), among others.  As research and clinical testing 
continued, and with the help of personal politics, some sequences have fallen out 
of favor.  Today, sequences that are still in use in some form or another with 
variable popularity are the T1-w sequence, T2-w sequence, DCE, DWI, and 
MRS.  There has been a movement in recent years in the development of 
terminology refinement for prostate MRI, one term that is quintessential is 
multiparametric.  This is how prostate MRI is described, as multiparametric MRI 
because the sequence selection is imaging multiple parameters of the tissues.   
The T1-weighted sequence provides clinicians with basic anatomy and 
morphology of the prostate and the surrounding tissues of the male pelvis.  This 
sequence is traditionally acquired in the axial or transverse plane.  Generally, the 
signal-to-noise ratio of the images for this sequence is good.  Unfortunately, the 
contrast-to-noise ratio is low, especially within the prostate itself, as the tissues 
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are not differentiated as finely by internal tissue borders as is clearly visible on 
histology slides.  However, if clinicians need to focus on the vasculature in the 
area, it is easily contrasted from surrounding tissues.  A typical T1-w sequence 
will have flip angles (FA) are > 500 and a TR of > 300ms.  Cancer of the prostate 
is not visible distinctly from the normal prostatic tissue, but after seeing another 
set of images for other sequences, it does become more readily apparent, for 
example T2-w imaging (Hedge et al, 2013). 
 
Figure 7: T2-weighted Imaging and Diffusion-weighted Imaging 
 
Image to the left is a T2-weighted image with the low signal or dark region is the 
area of prostate cancer.  The diffusion weighted image to the right confirms this 
with a reduced or restricted diffusion region that also appears dark (Thompson et 
al, 2013). 
 
T2-weighted imaging is used to provide detailed internal prostatic 
glandular structures, essentially assessing the anatomical zones and capsule 
that providing detection, localization, and staging.  This sequence is acquired in 
all three planes (axial, sagittal, coronal).  The parameters of this sequence 
varies, but traditionally the TR in the range of 2000 to 8000ms, TE in the range of 
70 to 170 ms, slice thickness of 3 mm with no gap, and the in plane matrix of 256 
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x 256.  The structural components of the gland visible in the images from this 
sequence allow for clinicians to identify suspicious lesions and determine 
whether the tumor burden is intracapsular invasion or extracapsular extension 
and possible seminal vesicle invasion.  This is possible due to high signal-to-
noise ratio and spatial resolution.  Prostate lesions will tend to appear as low 
signal intensities, which is juxtaposed to the surrounding normal high signal 
intensity of prostate’s peripheral zone.  This sequence, in the axial plane, needs 
to cover the entire prostate and all of the seminal vesicles.  It is important to 
understand that while this sequence is sensitive, it is not specific enough by itself 
to identify cancer lesions.  The T2-w sequence is susceptible to motion and 
hemorrhagic artifact, so precautions should be taken to limit such artifacts 
(Hedge et al, 2013; Alivatos and Pavlos, 2014; Barentsz et al, 2012). 
In the prostate, another important sequence is the diffusion-weighted 
imaging, which adds to the lesion characterization disambiguation.  Tumors tend 
to be regions of restricted movement on DW images relative to the other areas of 
the prostate.  The b-value selection is changed over time, but today there has 
been a move to higher b-values, so instead of using 0, 800, and 1000s/mm2, 
using b-values such as 0, 1000, 2000s/mm2.  By utilizing a single shot spin echo 
EPI sequence clinicians are able to limit motion artifact in individual slices, but 
the signal-to-noise ratio is unfortunately not high.  DWI sequences allow for 
apparent diffusion coefficient map (ADC map) to be computed, thus providing 
quantitative and qualitative analysis of prostate cancer aggressiveness.  In fact, 
 28 
ADC values that are lower are usually found to be cancerous tissues, and 
correlate to Gleason scores.  In any great mpMRI protocol for the prostate, this 
sequence is considered standard and should always be part of the regular MRI 
work-up (Hedge et al, 2013; Bloch et al, 2004; Manenti et al, 2014; Barentsz et 
al, 2012). 
The next sequence to be discussed is the dynamic contrast-enhanced 
imaging, which has high resolution (Barentsz et al, 2012).  DCE, more 
specifically, is done using a 3D SPGR like sequence, which is a T1-w sequence 
that has high temporal resolution.  In order to have clinical relevance, the 
sequence needs to be done in a timely manner and cannot consume a large 
amount of time.  The length of each dynamic needs to be long enough to capture 
the in-flow and out-flow of contrast of the prostate and surrounding tissues.  By 
allowing for the in-flow and out-flow to be charted, curves can be made to 
illustrate the various types of diffusion, otherwise known as the pharmacokinetics 
of the vasculature of the prostate.  Institutions vary some in how they would like 
their curves to be done.  Generally, the idea is to have one full dynamic without 
contrast, followed by a second dynamic where gadolinium contrast is injected 
during the dynamic, and as many dynamics after to the wash-in and wash-out of 
the contrast (Barentsz et al, 2012). 
The magnetic resonance spectroscopy sequence is the least used clinical 
prostate MRI scan.  MRS is able to look at metabolites in vivo by recording and 
analyzing their signal in the form of peaks caused by frequency shift, or 
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“chemical shift”, relative to the standard (Bushberg et al, 2012).  The premise 
being that the spectra will display metabolite peaks, such as phosphocholine, 
involved in cell turnover and proliferation, and creatine, temporary storage of 
phosphates, will be different in tumor regions compared to healthy tissue region.  
The scanning time for just this sequence alone is close to 20 minutes, which 
further complicates the view of utility in the clinical setting. 
 
Figure 8: Magnetic Resonance Spectroscopy of the Prostate 
 
The above figure is a chart of the spectroscopic peaks of prostate cancer tissue 
in a patient’s prostate, which is evident by the increased choline to citrate ratio 
(Thompson et al, 2013). 
 
The sequence design usually involves a STEAM, known as stimulated 
echo acquisition mode, and PRESS, known as point resolved spectroscopy, 
depending on preferences and experience of those employing the single voxel 
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technique (Bushberg et al, 2012).  Using the single voxel technique allows us to 
see all the possible metabolites present in the MRI trace for the prostate tissue, 
while still achieving a high signal-to-noise ratio (SNR).  The technique, whether 
single voxel or multivoxel, has higher SNR, scanning in less time, and higher 
spectral resolution when it is performed on the 3 Tesla scanners compared to the 
1.5 Tesla scanners.  The improvements come with the difficulties, such as what 
were once single peaks are now multiple peaks (Bushberg et al, 2012).  Prostate 
MRS needs to be done with an endorectal coil and tends to focus on citrate and 
choline, especially their ratio when examining possible tumor tissues compared 
to normal prostate tissues (Barentsz et al, 2012). 
Coils 
Coil selection has changed over time as prostate imaging has progressed.  
The coils that have been used in prostate MRI have been the body coil, the 
pelvic phased array coil, and the endorectal surface coil.  The body coil was 
initially the only coil for prostate MRI in the early to mid- 1980s.  As researchers 
and clinicians alike developed a better understanding of prostate MRI and 
continued to innovate, the pelvic phased array coil and endorectal surface coil 
came along.  The pelvic phased array coil provided higher SNR, and maintained 
patient comfort, but did not allow clinicians to have the small FOV that they 
needed.  Today, doctors have the endorectal surface coil.  The coil allows for 
increased SNR and decreased motion artifact, this is essential for MRI 
sequences, such as DWI and MRS (Hedge et al, 2013). 
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Scanners 
Prostate imaging has been done strictly on the 1.5T and 3.0T MRI 
scanners since its inception.  The 1.5T scanner is useful because it has less 
magnetic field inhomogeneity, compared to the 3T scanner.  By today’s 
standards and capabilities in prostate MRI, clinicians need the increased signal 
of the pelvic phased array coil combined with the endorectal surface coil.  On the 
other hand, clinicians can chose to get the same signal as the 1.5T with 
endorectal coil, or may forego the endorectal coil with the 3T scanner.  This 
definitely improves the experiences of the patient, but other ethical questions 
about clinical standards emerge (Hedge et al, 2013). 
Reporting 
Clinical reports of mpMRI findings of the prostate have traditionally varied 
in layout and terminology.  The reports are further complicated by inter-observer 
variability in expertise and comprehension in prostate MRI.  The complexities of 
this type of imaging can be read at the clinical level by just anyone, it requires 
considerable training, and learning combined with experience.  As the number of 
clinicians proficient in prostate MRI has grown, so has the conscious 
understanding that there needs to be a unified layout or format to allow for other 
doctors to comprehend the findings of the imaging results.  Recently clinicians 
have been gathering to discuss and produce standards in reporting of prostate 
cancer imaging results, more specifically clinical MRI. 
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In 2012, the European Society of Urogenital Radiology (ESUR) gathered 
experts on prostate MRI from all over Europe.  They wanted to form guidelines 
for scanning and reporting of prostate cancer.  They developed suggested 
minimum requirement protocols for “detection”, “staging”, and “node and bone” 
directing the use and parameters for T2-w, DWI, DCE, and MRS (Barentsz et al, 
2012).  There was conversation about the use of a standardized scoring system 
of prostate imaging, similar to what breast radiologists have employed called BI-
RADS, which they decided to call PI-RADS.  A revolutionary aspect of the 
scoring system is that there needs to be a clinical significance grade or score 
associated, which is valuable, as it provides other clinicians viewing the report an 
idea of the confidence the radiologist has in their findings (Barentsz et al, 2012). 
Learning from Others 
It is important to have the perspective of clinicians caring for patients by 
characterizing, staging, and treating the disease.  This allows for a more 
complete understanding of the present state of prostate cancer and clinical 
imaging.  Three urologists and three radiologists were contacted about interest in 
being interviewed regarding the value of MRI as a diagnostic tool.  The premise 
of each meeting was to discuss prostate cancer and imaging from their point of 
view, both their experience and thoughts.  The physicians were selected at 
Boston Medical Center, Beth Israel Deaconess Medical Center, and Brigham and 
Women’s Hospital based on the amount of experience they had in this area.  The 
interviews were conducted at their convenience and ranged from 15 minutes to 
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90 minutes along.  All interviews were recorded and summarized.  The questions 
were all very similar, but curtailed to their particular interests and experience.  
The discussion section is a summation of those interviews.
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Discussion 
 
 
Upon review of the literature and interviews with health care professionals the 
following conclusions have been drawn. 
Current Opinion in the Department of Urology, Boston Medical Center 
Conclusions from interviews with several urologists at Boston Medical 
Center have led to the observations that follow.  Urology today has undergone a 
deep revolution in clinical practices for prostate cancer and the use of MRI.  
Urologists are utilizing MRI with increased frequency for several reasons.  Firstly, 
MRI provides improved sensitivity compared to US imaging.  This allows for 
doctors to view prostate cancer metastasis involved in capsular penetration and 
seminal vesicle involvement, while providing a superior three dimensional global 
image of the prostate.  Secondly, doctors have the ability to put patients in the 
early stages of disease for prostate into various programs for monitoring 
(“watchful waiting”), treating (radiation, surgery, etc), or staging in a logical 
evidence based manor.  This reason is crucial to understand because it has led 
to the development and use of active surveillance.  The third reason is prostate 
cancer patients are able to have their prostates imaged in areas of the prostate 
that random biopsy would traditionally miss, which ultimately allows for targeted 
biopsies.  Urologists see that MRI allows them to treat prostate cancer like every 
other disease, by providing doctors with the ability to view the cancer through 
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imaging and focus on targeted areas.  This new found capability doctors have, is 
seen as a major change, since traditionally the malignancy was treated and 
biopsied in a random and in a less targeted manner.  The exam is long, about 30 
to 45 minutes, which is not tolerable for all patients, according to urologists.  
Furthermore, in the USA, the Urology community understands in order to fully 
utilize MRI, there needs to be a radiologist who is an expert or has expertise in 
reading prostate MRI (R. Babayan and M. Katz, personal communication, May 
27, 2014; D. Wang, personal communication, June 3, 2014). 
Current Opinion of Radiologists in the Boston Area 
The following observations have been drawn based on interviews to 
several seasoned radiologists in the Boston area.  Radiology has constantly 
evolved in the clinical setting, especially in the imaging of prostate cancer.  In 
particular, MRI has evolved from two sequence scanning protocol of T1-w and 
T2-w imaging in the early 1980s that did not utilize an endorectal coil, due to it 
not being developed at that time in MRI history, to today clinical imaging utilizes 
mpMRI with endorectal coil in a 3T scanner.  A strong prostate MRI program at 
any clinical institution, today, just needs one sequence protocol with endorectal 
coil at a 3T scanner to efficiently image prostate cancer at a high volume.  This 
requires DWI, T2-w, and DCE sequences to carry out the routine needs of the 
clinical setting, which are detection, characterization, and staging.  MRI has 
become the best medical imaging modality for early detection and staging of 
prostate cancer.  US or TRUS do not play a clinical role for radiologists today as 
 36 
a diagnostic or staging tool.  Computed tomography and nuclear medicine are 
not ideal for early detection of prostate cancer, but still remain effective at 
detecting advanced stage prostate cancer.   
Regarding reports and notation for prostate cancer patients, European 
Radiologists, those associated with ESUR, have made strides in recent years to 
standardize them under PI-RADS.  USA radiologists have not developed a 
standardization of reporting, such as PI-RADS, but a group in eastern USA has 
been working to publish a suggested standardized way of reporting and notation.  
In fact, radiologists in eastern USA are suggesting that prostate MRI could 
become part of the normal work-up for eligible men, which is already standard 
practice in Europe.  On an international level, radiologists are increasingly 
agreeing about the value of MRI as a diagnostic tool to identify and monitor 
prostate cancer (C.M. Tempany, personal communication, May 28, 2014; N. 
Rofsky, personal communication, June 4, 2014; M. Smith, personal 
communication, June 4, 2014). 
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